Clover Bio-B (02197) rose nearly 5%. As of press release, it was up 4.92% to HK$0.64, with a turnover of HK$1,464,200.
The Zhitong Finance app learned that Clover Bio-B (02197) rose nearly 5%. As of press release, it was up 4.92% to HK$0.64, with a turnover of HK$1,464,200.
According to the news, Clover Biotech announced that in the phase I human clinical trial of the evaluation company's RSV preF-trimeric subunit vaccine candidate (SCB-1019), the first batch of subjects has been enrolled. The vaccine candidate was developed based on Clover Biotech's unique innovative protein trimerization (Trimer-Tag) vaccine technology platform.
According to reports, the phase I clinical trial initiated in Australia is a randomized, placebo-controlled study to evaluate the safety, reactogenicity, and immunogenicity of SCB-1019 in different dosage forms and dosage levels among young adults and the elderly. Safety and immunogenicity results are expected to be published in the second half of 2024.